131 related articles for article (PubMed ID: 9468023)
21. Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft.
Gu W; Yudistiro R; Hanaoka H; Katsumata N; Tsushima Y
Ann Nucl Med; 2021 Apr; 35(4):514-522. PubMed ID: 33582981
[TBL] [Abstract][Full Text] [Related]
22. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
23. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
24. Avidin targeting of intraperitoneal tumor xenografts.
Yao Z; Zhang M; Sakahara H; Saga T; Arano Y; Konishi J
J Natl Cancer Inst; 1998 Jan; 90(1):25-9. PubMed ID: 9428779
[TBL] [Abstract][Full Text] [Related]
25. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin.
Saga T; Weinstein JN; Jeong JM; Heya T; Lee JT; Le N; Paik CH; Sung C; Neumann RD
Cancer Res; 1994 Apr; 54(8):2160-5. PubMed ID: 8174123
[TBL] [Abstract][Full Text] [Related]
26. Pretargeted radioimmunotherapy.
Meredith RF; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
[TBL] [Abstract][Full Text] [Related]
27. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
28. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
[TBL] [Abstract][Full Text] [Related]
29. Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: studies in a nude mouse xenograft model.
Maraveyas A; Rowlinson-Busza G; Murray S; Epenetos AA
Int J Cancer; 1998 Nov; 78(5):610-7. PubMed ID: 9808531
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding.
Sung C; van Osdol WW
J Nucl Med; 1995 May; 36(5):867-76. PubMed ID: 7738665
[TBL] [Abstract][Full Text] [Related]
31. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
32. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Foulon CF; Bigner DD; Zalutsky MR
Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin.
Rosebrough SF
Nucl Med Biol; 1993 Jul; 20(5):663-8. PubMed ID: 8358353
[TBL] [Abstract][Full Text] [Related]
34. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
[TBL] [Abstract][Full Text] [Related]
35. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin.
van Osdol WW; Sung C; Dedrick RL; Weinstein JN
J Nucl Med; 1993 Sep; 34(9):1552-64. PubMed ID: 8355076
[TBL] [Abstract][Full Text] [Related]
36. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
[TBL] [Abstract][Full Text] [Related]
37. Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens.
Yang Q; Parker CL; Lin Y; Press OW; Park SI; Lai SK
J Control Release; 2017 Jun; 255():73-80. PubMed ID: 28363519
[TBL] [Abstract][Full Text] [Related]
38. Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody.
Hnatowich DJ; Fritz B; Virzi F; Mardirossian G; Rusckowski M
Nucl Med Biol; 1993 Feb; 20(2):189-95. PubMed ID: 8448574
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting.
Chinol M; Paganelli G; Sudati F; Meares C; Fazio F
Nucl Med Commun; 1997 Feb; 18(2):176-82. PubMed ID: 9076775
[TBL] [Abstract][Full Text] [Related]
40. Disulfide bond-targeted radiolabeling: tumor specificity of a streptavidin-biotinylated monoclonal antibody complex.
del Rosario RB; Wahl RL
Cancer Res; 1990 Feb; 50(3 Suppl):804s-808s. PubMed ID: 2297728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
